

# ISLHD HAEMATOLOGY CLINICAL TRIALS

## *Illawarra Cancer Care Centre*

January 2024

### **ISLHD CANCER CLINICAL TRIALS UNIT**

**Illawarra Cancer Care Centre  
Wollongong Hospital  
Loftus Street  
Wollongong NSW 2500**

**Ph: 02 4253 4384**

**Fax: 02 4222 5085**

**Email: ISLHD-  
CancerClinicalTrials@health.  
nsw.gov.au**

Clinical Trials available  
through the Illawarra  
Shoalhaven Local Health  
District can be found on  
the ClinTrial Refer App.  
Scan the QR code below  
to download ClinTrial  
Refer.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Lymphoma (Non-Hodgkins and Hodgkins)
- Myelodysplastic syndromes
- Myelofibrosis
- Multiple Myeloma

### **REFERRAL OR CONSULTATION**

To discuss your patient with an ISLHD  
Haematology Trials Clinician, please phone  
Haematology on 02 4253 4009

# ISLHD Haematology Clinical Trials

## **\*\*CURRENTLY OPEN FOR RECRUITMENT\*\***

*Scan the QR Code for more information including eligibility criteria*

### **Multiple Myeloma**

**CA057-001:** A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM).

Dr Parmar  
Kiara Porter /  
Danielle Di  
Pietro  
**\*Satellite site**



**IRAKLIA:** A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM).

Dr Parmar  
Tiffany  
Koutsouradis  
/ Jillian  
Dubose



**IZALCO:** A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM).

Dr Parmar  
Felicity Car-  
roll-Cross /  
Amelia Fe-  
neck



**MonumenTAL-2:** A multi-arm phase 1b study of talquetamab with other anticancer therapies in participants with multiple myeloma.

Dr Parmar  
Edwina Petre  
/ Kiara Porter




**TCD17710:** First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light chain amyloidosis (RRLCA).

Dr Parmar  
Felicity Car-  
roll-Cross /  
Carla Brown



**LTS17704:** International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study. **\*\*Opening soon\*\***

Dr Parmar  
Tiffany  
Koutsouradis



# ISLHD Haematology Clinical Trials

## **\*\*CURRENTLY OPEN FOR RECRUITMENT\*\***

*Scan the QR Code for more information including eligibility criteria*

### **Myelo-dysplastic syndromes & AML**

**CA059-001:** A phase 1, open-label, dose finding study of CC-95251 alone and in combination with antineoplastic agents in subjects with acute myeloid leukemia and myelodysplastic syndromes. **\*\*current recruitment hold\*\***

Dr Presgrave  
Kiara Porter



### **Myelofibro-sis**

**CA011-023:** A phase 1b study of BMS-986158 monotherapy and in combination with either ruxolitinib or fedratinib in participants with DIPSS-intermediate or high risk myelofibrosis (CA011-023).

Dr Presgrave  
Kiara Porter /  
Danielle Di  
Pietro



### **Acute Leukaemia**

**AML M22/D2:** The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Dr Presgrave  
Carla Brown



### **Lymphoma**

**NHL30 - PETReA:** Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma.

Dr Presgrave  
Angela  
Murphy



**For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email [ISLHD-HaematologyTrials@health.nsw.gov.au](mailto:ISLHD-HaematologyTrials@health.nsw.gov.au)**

<b>Trial Coordinator</b>	<b>Availability</b>	<b>Contact details</b>
Danielle Di Pietro (team leader)	Mon-Fri	02 4255 1415
Felicity Carroll-Cross	Mon-Fri	02 4253 4039
Carla Brown	Tues-Thurs	02 4253 4082
Tiffany Koutsouradis	Wed-Fri	02 4253 4082
Angela Murphy	Mon-Fri	Angela.Murphy6@health.nsw.gov.au
Kiara Porter	Mon-Fri	02 4222 5276
Jillian Dubose	Tues-Fri	02 4255 1495
Amelia Feneck	Mon-Wed	02 4222 5230
Edwina Petre	Mon, Wed, Thurs	02 4253 4173